Free Trial

Twist Bioscience (TWST) Stock Forecast & Price Target

Twist Bioscience logo
$47.94 +4.32 (+9.90%)
(As of 12/20/2024 05:31 PM ET)

Twist Bioscience - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
1
Buy
8

Based on 10 Wall Street analysts who have issued ratings for Twist Bioscience in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 1 has given a sell rating, 1 has given a hold rating, and 8 have given a buy rating for TWST.

Consensus Price Target

$51.90
8.26% Upside
According to the 10 analysts' twelve-month price targets for Twist Bioscience, the average price target is $51.90. The highest price target for TWST is $60.00, while the lowest price target for TWST is $35.00. The average price target represents a forecasted upside of 8.26% from the current price of $47.94.
Get the Latest News and Ratings for TWST and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Twist Bioscience and its competitors.

Sign Up

TWST Analyst Ratings Over Time

TypeCurrent Forecast
12/23/23 to 12/22/24
1 Month Ago
11/23/23 to 11/22/24
3 Months Ago
9/24/23 to 9/23/24
1 Year Ago
12/23/22 to 12/23/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
8 Buy rating(s)
4 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$51.90$51.78$48.22$28.17
Forecasted Upside8.26% Upside22.61% Upside6.47% Upside-23.38% Downside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

TWST Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TWST Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Twist Bioscience Stock vs. The Competition

TypeTwist BioscienceMedical CompaniesS&P 500
Consensus Rating Score
2.70
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside8.26% Upside25,827.32% Upside14.53% Upside
News Sentiment Rating
Positive News

See Recent TWST News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/13/2024Wolfe Research
3 of 5 stars
D. Schenkel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$60.00+26.61%
11/26/2024TD Cowen
5 of 5 stars
 Reiterated RatingBuy ➝ Buy$58.00 ➝ $58.00+23.72%
11/19/2024Barclays
3 of 5 stars
 Lower TargetOverweight ➝ Overweight$55.00 ➝ $52.00+26.80%
11/19/2024Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSector Outperform ➝ Sector Outperform$50.00 ➝ $54.00+32.19%
11/19/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$46.00 ➝ $48.00+15.86%
10/17/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$45.00 ➝ $48.00+4.58%
This is the worst sign for the U.S. stock market in 50 years (Ad)

The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"

Click here to see Dan's new, urgent warning about the U.S. market for 2025.
10/1/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$52.00 ➝ $56.00+30.99%
8/5/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderweight ➝ Underweight$28.00 ➝ $35.00-17.59%
7/9/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$45.00 ➝ $55.00+10.84%
6/4/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Nambi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$53.00+20.43%
9/27/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$27.00+35.88%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:29 AM ET.


TWST Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Twist Bioscience is $51.90, with a high forecast of $60.00 and a low forecast of $35.00.

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last twelve months. There is currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TWST shares.

According to analysts, Twist Bioscience's stock has a predicted upside of 8.26% based on their 12-month stock forecasts.

Twist Bioscience has been rated by research analysts at Barclays, Evercore ISI, Leerink Partners, Robert W. Baird, Scotiabank, TD Cowen, and Wolfe Research in the past 90 days.

Analysts like Twist Bioscience less than other "medical" companies. The consensus rating score for Twist Bioscience is 2.70 while the average consensus rating score for "medical" companies is 2.81. Learn more on how TWST compares to other companies.


This page (NASDAQ:TWST) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners